Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Arbutus Biopharma CorporationNASDAQ: ABUS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $1.36M fell 61.9% year over year, behind the +74.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 90.9% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Stock-based compensation amounted to 49.4% of revenue in FY2025, down 96.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -61.9% toward the trailing-twelve-month pace of +74.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.95M USD
- Year-over-year change
- -22.6%
- 4-year CAGR
- +2.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.95M | -22.6% |
| FY2024 | 2024-12-31 | 8.99M | -3.4% |
| FY2023 | 2023-12-31 | 9.3M | +29.5% |
| FY2022 | 2022-12-31 | 7.18M | +11.8% |
| FY2021 | 2021-12-31 | 6.42M | — |
Stock-Based Compensation vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 stock-based compensation of $18.43M is the 4th largest of the 9 companies compared; the peer median is $16.63M.
- Its year-over-year change of +74.9% is the 2nd highest of 8, against a peer median of +10.1%.
- Stock-based compensation amounts to 9.6% of revenue for ABUS, versus a peer median of 18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $336.62M | +10.1% | +14.7% | 7.0% | |
| LTM Sep 2026 | $68.15M | +7.5% | -4.5% | 15.1% | |
| LTM Mar 2026 | $35.01M | +17.1% | -21.7% | 53.5% | |
| LTM Mar 2026 | $18.43M | +74.9% | -1.1% | 9.6% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $14.34M | — | -14.0% | 1556.3% | |
| LTM Mar 2026 | $12.56M | +183.6% | +171.6% | — | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| Peer median (excluding ABUS) | $16.63M | +10.1% | -11.3% | 18.9% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Deferred Income Tax | (8.18M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Change in Working Capital | 930K | 29.24M | (18.23M) | (2.83M) | (10.02M) |
| Accounts Receivables | 413K | (453K) | (424K) | (633K) | 1.38M |
| Inventory | (1.91M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.91M | 5.22M | 0 | 0 | (2.11M) |
| Other Working Capital | 517K | 24.48M | (17.81M) | (2.2M) | (9.29M) |
| Other Non-Cash Items | 7.79M | (3.75M) | (5.56M) | (2.47M) | (3.43M) |
| Operating Cash Flow | (67.53M) | (35.36M) | (85.94M) | (64.85M) | (39.64M) |
| Capital Expenditures | (809K) | (512K) | (1.01M) | (182K) | 0 |
| Acquisitions (Net) | 1.81M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.22M) | (130.43M) | (80.51M) | (141.51M) | 12.87M |
| Sales of Investments | 70.35M | 56M | 132.27M | 164.64M | 155.28M |
| Other Investing Activities | (1.81M) | 0 | 20K | 0 | (152.56M) |
| Investing Cash Flow | (12.68M) | (74.94M) | 50.77M | 22.95M | 15.58M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 134.67M | 20.32M | 29.85M | 44.12M | 5.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (12.14M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.71M | 11.49M | 795K | 7.87M | 0 |
| Financing Cash Flow | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Effect of Forex Changes | 5K | (22K) | 25K | (49K) | 14K |
| Net Change in Cash | 57.03M | (78.51M) | (4.49M) | 10.05M | (18.32M) |
| Free Cash Flow | (68.34M) | (35.87M) | (86.94M) | (65.03M) | (39.64M) |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.